GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PureTech Health PRTC.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

114.40p

-1.38%

Close of 20 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

PureTech Health — daily PRTC

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View PureTech Health on TradingView ↗
Market value
£292.9m
Last close × shares
Volume
1.9m
Shares, 20 Nov 2026

About PureTech Health

Its shares trade on LSE under the ticker PRTC.L. It has been listed since 19 June 2015. In the fiscal year to 31 December 2025, it reported revenue of $4.8m and a net loss of $112.2m. At that date it held total assets of $535.6m and shareholders' equity of $312.6m.

PureTech Health Plc is a cross-disciplinary bio-pharmacy company, which engages in the development of treatment programs for obesity, cognitive disorders, baldness, depression, allergy, and autoimmune. The company is headquartered in Boston, Massachusetts. The company went IPO on 2015-06-19. The firm is engaged in discovering, developing and commercializing medicines for diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders, and inflammatory and immunological diseases, among others. Its segments include Internal and Affiliates. The Internal division is focused on advancing a pipeline fueled by discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. The Affiliates segment is comprised of the programs within its Affiliates division that are consolidated operational subsidiaries that have research and development programs. Its wholly owned pipeline includes various candidates, such as LYT-100, LYT-200, LYT-210, Lymphatic Targeting Chemistry Platform, Milk Exosome Platform and Meningeal Lymphatics Platform.

Figures and description from our data supplier, not checked against the company's own report.

More about PureTech Health →

Latest on PureTech Health

Our reporting

Next results

29 Apr 2027

Due on 29 Apr 2027. Analysts expect earnings of -0.09 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is PureTech Health's ticker?

PureTech Health trades as PRTC.L on LSE, under ISIN GB00BY2Z0H74.

What was PureTech Health's last closing price?

114.40p on 20 Nov 2026. The figure is in GBp and is never converted.

When does PureTech Health next report results?

Results are expected on 29 Apr 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.